Elicera Therapeutics AB (publ)

Stockholm Stock Exchange ELIC.ST

Elicera Therapeutics AB (publ) Net Income Margin for the year ending December 31, 2023: -146.02%

Elicera Therapeutics AB (publ) Net Income Margin is -146.02% for the year ending December 31, 2023, a 90.42% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.
  • Elicera Therapeutics AB (publ) Net Income Margin for the year ending December 31, 2022 was -1,524.37%, a 99.93% change year over year.
  • Elicera Therapeutics AB (publ) Net Income Margin for the year ending December 31, 2021 was -2,235,352.30%.
Key data
Date Net Income Margin EBITDA Margin EBIT Margin EBITDA
Market news
SV Wall Street
Stockholm Stock Exchange: ELIC.ST

Elicera Therapeutics AB (publ)

CEO Mr. Jamal El-Mosleh M.Sc.
IPO Date June 11, 2021
Location Sweden
Headquarters World Trade Center GOeteborg
Employees 2
Sector Healthcare
Industries
Biotechnology Clinical Trials Vaccines
Description

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.

Similar companies

COMBI.ST

CombiGene AB (publ)

USD 0.21

1.47%

StockViz Staff

February 5, 2025

Any question? Send us an email